摘要
Severe acute respiratory syndrome coronavirus 2(SARSCov-2)is the etiologic agent of the coronavirus disease 19(COVID-19)pandemic.In viral infections like SARS-CoV-2,a robust anti-viral type 1 immune response,including upregulation of type 1 CD4+T helper cells(Th1),is required for effective viral clearance while minimizing end-organ pathology and collateral tissue damage.
基金
supported by immunophenotyping assessment in a COVID-19 cohort(IMPACC)and has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases,National Institutes of Health,under Contract numbers NO1-Al-25496 and NO1-Al-25482
Nancy Chang,Ph.D.Award for Research Excellence,Baylor College of Medicine.
